Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Tinea”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 73 records · Page 4Linked to original sources
PubMedDate not supplied

Once-daily naftifine cream 1% in the treatment of tinea cruris and tinea corporis.

Seventy patients with tinea cruris or tinea corporis were treated with naftifine cream 1% or vehicle once daily for 4 weeks in this double-blind, randomized study. After two weeks, the patients using naftifine had a significantly higher mycologic cure rate than the vehicle-treated patients (79% vs. 31%, p less than 0.001), and they showed significantly better resolution of signs and symptoms. Statistically significantly differences favoring naftifine over its vehicle were found throughout the treatment period and 2 weeks posttreatment.

Adolescent↗
PubMedDate not supplied

Topical treatment of tinea corporis and tinea cruris with eberconazole (WAS 2160) cream 1% and 2%: a phase II dose-finding pilot study.

In a phase II pilot dose-finding study 60 patients with mycologically proven tinea corporis and tinea cruris were treated with eberconazole cream 1% once daily (group A, 15 patients), 1% twice daily (group B, 15 patients), 2% once daily (group C, 15 patients) or 2% twice daily (group D, 15 patients). Treatment was continued for 2 weeks after clinical cure; the maximum duration of treatment was limited to 6 weeks. The characteristics of the four groups of patients, distribution of the target lesions, clinical sum of baseline scores and infecting organisms were similar. Statistical examination showed that the mean time of appearance in weeks of negative microscopy and culture was similar in the four groups. There was no significant difference between the groups in terms of the range and mean duration of treatment. By the end of the study, treatment was effective in 13 patients (87%) in group A, 14 (93%) in group B and 11 (73%) in both groups C and D (mycological cure and clinical cure or residual minimal signs and symptoms). One patient in group A did not respond to treatment and two patients in group C had to withdraw because of side-effects. No undesirable effects or significant changes were seen in the blood tests. At the assessment 6 weeks post therapy, eberconazole was judged to have been effective in 93% of patients in group A, 100% of patients in groups B and D and 61% of patients in group C. Although not statistically significant, a trend towards more favourable results was seen in group B when considering the mean time of appearance of clinical cure and negative KOH and culture.

Administration, Topical↗
PubMedDate not supplied

Tinea axillaris, a variant of intertriginous tinea, due to non-occupational infection with Trichophyton verrucosum.

The term tinea axillaris has been used only a few times in the literature. In this paper we describe a male patient with widespread tinea corporis and unguium affecting also both axillary regions. Trichophyton verrucosum was isolated as the causative agent. The patient admitted to no direct contact with infected animals, but had lived in a rural area until a year before the infection became widespread. Topical treatment with glucocorticosteroids probably promoted propagation over large parts of his body and may have led to the infection of the axillary region, an unusual site for fungal infection. Treatment with itraconazole over 4 weeks led to complete clearing of all lesions on glabrous skin. Thereafter, itraconazole pulse therapy was used to treat the nail infection.

Animals↗
PubMed1998

Itraconazole in the treatment of tinea corporis and tinea cruris: comparison of two treatment schedules.

The efficacy and safety of two dos-ages of itraconazole in the treatment of tinea corporis or cruris were compared in a multicentre, randomized, double-blind, parallel-group trial. Fifty-four patients received itraconazole 100 mg daily for 2 weeks and 60 received itraconazole 200 mg daily for 1 week. After a 6-week follow-up period, mycological cure was achieved in 70% of patients in the 100 mg/2 weeks group and in 60% of those in the 200 mg/1 week group (not significantly equivalent); in the worst-case and intention-to-treat analyses, mycological cure rates (45-49%) were borderline equivalent at the end of follow-up. Clinical response was seen in 80% of evaluable patients in the 100 mg/2 weeks group and in 73% in the 200 mg/1 week group at the end of follow-up (borderline equivalent). Similar results were found in the intention-to-treat analysis. The tolerability ratings for the two regimens were significantly equivalent. Thirteen patients (24%) in the 100 mg/2 weeks group but only nine (15%) in the 200 mg/1 week group reported adverse events during treatment. Two patients in the 200 mg/1 week group stopped treatment because of adverse events. No clinically significant changes were seen in laboratory parameters in either treatment group. This trial showed that itraconazole 200 mg for 1 week is similarly effective, equally well tolerated and at least as safe as the established regimen of itraconazole 100 mg for 2 weeks in the treatment of tinea corporis or cruris.

Adolescent↗
PubMed1998

Fluconazole in the treatment of tinea corporis and tinea cruris.

BACKGROUND: Results of topical dermatomycosis treatment are often unsatisfactory, particularly in patients with extended or multiple infection sites. OBJECTIVE: Given the high fluconazole concentrations attainable in the stratum corneum and the long elimination half-life of fluconazole, we investigated whether efficacy is satisfactory when using fluconazole at once weekly doses of 150 mg. METHODS: In an open, noncomparative study, tinea corporis and cruris patients were treated with once weekly fluconazole 150 mg over 2-4 weeks. Clinical (pruritus, erythema, scaling, burning/pain, vesiculation) and mycologic (culture and microscopy) assessments were performed before treatment, at weekly intervals until the end of treatment and 3 weeks after treatment. All adverse events were recorded. RESULTS: The total severity scores of clinical symptoms were reduced from 7.1 before to 1.5 after treatment (p = 0.001, n = 100 patients). Seven patients experienced adverse events. CONCLUSIONS: Fluconazole 150 mg once weekly for 2-4 weeks is an efficacious and safe regimen in the treatment of tinea corporis and cruris.

Antifungal Agents↗
PubMed1984

Bifonazole cream: once-a-day application every second day in tinea cruris and tinea corporis.

The efficacy and local tolerance of Bay h 4502 1% cream were investigated in Tinea corporis and Tinea cruris. This biometrically designed, noncontrolled study was carried out in 32 patients (27 males and 5 females). The mean values of age, height and body weight were 25 years, 160.7 cm and 65.7 kg. Bay h 4502 1% cream was applied once daily every second day for 2 weeks. Mycological and clinical controls were carried out 1 week after starting therapy as well as 3 days and 2 weeks after the end of therapy. The direct microscopic examination was negative in 28/28 patients (100%) after the end of therapy as well as at the follow-up examination in 32/32 patients (100%). No pathogenic organisms were seen in 20/28 patients (71%) at the end of therapy and in 28/32 patients (88%) at the follow-up control. The overall success rate shows an analogous picture: 'very good' and 'good' was assessed for 26 patients (81%) at the end of therapy. In 50% of patients the onset of improvement occurred within 5 days after start of treatment, and between the 6th and 12th day in a further 47%. The local tolerance was good. The results obtained show that there is no difference by this study in comparison with previous studies with a treatment once daily every day. This gives additional safety by minimizing the risk of failures in all those patients sometimes not following strictly doctor's advise.

Adult↗
PubMed1992

A comparison of itraconazole and griseofulvin in the treatment of tinea corporis and tinea cruris: a double-blind study.

A total of 40 patients with clinically and mycologically documented tinea corporis or tinea cruris were treated with 100 mg/day itraconazole (n = 19) or 500 mg/day griseofulvin (n = 21) for 15 days. Of the itraconazole-treated patients, 83.3% were healed or markedly improved, i.e. 'responders', after 15 days compared with 85.7% of griseofulvin-treated patients. At 15 days after the end of treatment, 88.2% of itraconazole- and 80.9% of griseofulvin-treated patients were classed as 'responders'. The mycological cure rate (both microscopy and culture negative) was generally lower than the clinical response rate. Both treatments were equally effective at the end of 15 days' treatment with 66.7% of patients cured, but itraconazole was superior to griseofulvin at the 15-day follow-up visit (77.8% of itraconazole-treated patients compared with 66.7% of griseofulvin-treated patients were cured). Both therapies were well tolerated; only one patient treated with itraconazole reported minor side-effects (dizziness, headache and gastro-intestinal disturbances). The results confirm those of earlier comparative trials and suggest that griseofulvin-treated patients are more at risk of relapse than are itraconazole-treated patients.

Adolescent↗
PubMed1985

Treatment of tinea corporis or tinea cruris with bifonazole 1% gel: an open, multicentre study.

An open, multicentre study was carried out in 103 patients with confirmed dermatophyte infections (tinea cruris or tinea corporis). The fungi isolated were Tr. rubrum (45), Tr. mentagrophytes (11), Ep. floccosum (26) and M. canis (21). All patients were treated with a single daily application of bifonazole (1% gel) and the duration of treatment was 3 weeks. Weekly clinical controls were performed during the therapeutic period and at least two clinical and mycological examinations were given after the end of treatment. Treatment was evaluated according to the clinical and mycological findings at the 14th post-therapeutic day. The results obtained were classified as very good in 80 patients, good in 11, moderate in 11 and failure in 1 patient. Local tolerance was very good and no side-effects were observed in any patients.

Adolescent↗
PubMed1999

Bilateral tinea nigra plantaris and tinea nigra plantaris mimicking melanoma.

Tinea nigra, a superficial fungal infection caused by Phaeoannellomyces werneckii, presents as a hyperpigmented, nonscaling macule of variable size and shape. Typically lacking induration, erythema, or pruritus, these "ink spot" lesions may resemble junctional nevi or malignant melanoma. Rapid, noninvasive diagnosis can be provided by potassium hydroxide examination, demonstrating numerous large, dematiaceous hyphae.

Adult↗
PubMed1989

Onychomycosis, tinea pedis and tinea manuum caused by non-dermatophytic filamentous fungi.

Over 4000 cases of fungal nail, sole and palm infection recorded during a three-year study period were investigated to determine the prevalence and significance of etiologic agents other than dermatophytes and yeasts. Littman's oxgall agar, which permitted isolation of cycloheximide-sensitive species but restricted overgrowth by fast growing contaminants, was used to promote isolation of these disease agents. Non-dermatophytic filamentous fungi made up 2.3% of the confirmed etiologic agents obtained overall, and constituted 3.3% of the agents obtained from nail infections. The most common species were Scopulariopsis brevicaulis, Hendersonula toruloidea, and Aspergillus sydowii. Scytalidium hyalinum was recorded for the first time from Canada, and an instance of nail infection by Gymnascella dankaliensis was recorded. Only H. toruloidea and Sc. hyalinum caused palm and sole infections.

Foot Dermatoses↗